Dasotraline Free Base

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 413478

CAS#: 675126-05-3 (free base)

Description: Dasotraline Free Base inhibits both dopamine and norepinephrine transporters and is used in the treatment of Attention Deficit Hyperactivity Disorder (ADHD)

Chemical Structure

img
Dasotraline Free Base
CAS# 675126-05-3 (free base)
Instruction

Theoretical Analysis

MedKoo Cat#: 413478
Name: Dasotraline Free Base
CAS#: 675126-05-3 (free base)
Chemical Formula: C16H15Cl2N
Exact Mass: 291.06
Molecular Weight: 292.200
Elemental Analysis: C, 65.77; H, 5.17; Cl, 24.26; N, 4.79

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 675126-05-3 (free base)   675126-08-6 (HCl)    

Synonym: Dasotraline Free Base

IUPAC/Chemical Name: (1R,4S)-4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-amine

InChi Key: SRPXSILJHWNFMK-MEDUHNTESA-N

InChi Code: InChI=1S/C16H15Cl2N/c17-14-7-5-10(9-15(14)18)11-6-8-16(19)13-4-2-1-3-12(11)13/h1-5,7,9,11,16H,6,8,19H2/t11-,16+/m0/s1

SMILES Code: N[C@@H]1CC[C@@H](C2=CC=C(Cl)C(Cl)=C2)C3=C1C=CC=C3

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: to be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
To be determined 0.0 100.00

Preparing Stock Solutions

The following data is based on the product molecular weight 292.20 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Vandana P, Arnold E. Dasotraline in ADHD: novel or me too drug? Expert Rev Neurother. 2019 Apr;19(4):311-315. doi: 10.1080/14737175.2019.1593826. Epub 2019 Mar 26. PMID: 30871381.

2: Findling RL, Adler LA, Spencer TJ, Goldman R, Hopkins SC, Koblan KS, Kent J, Hsu J, Loebel A. Dasotraline in Children with Attention-Deficit/Hyperactivity Disorder: A Six-Week, Placebo-Controlled, Fixed-Dose Trial. J Child Adolesc Psychopharmacol. 2019 Mar;29(2):80-89. doi: 10.1089/cap.2018.0083. Epub 2019 Jan 29. PMID: 30694697.

3: Yang X, Ryu S, Di L. Dasotraline as a selective cytochrome 2B6 inhibitor for reaction phenotyping. Biopharm Drug Dispos. 2019 Nov;40(9):358-361. doi: 10.1002/bdd.2207. PMID: 31674039.

4: Wigal SB, Hopkins SC, Koblan KS, Childress A, Kent JM, Tsai J, Hsu J, Loebel A, Goldman R. Efficacy and Safety of Dasotraline in Children With ADHD: A Laboratory Classroom Study. J Atten Disord. 2020 Jan;24(2):192-204. doi: 10.1177/1087054719864644. Epub 2019 Aug 2. PMID: 31375051.

5: Grilo CM, McElroy SL, Hudson JI, Tsai J, Navia B, Goldman R, Deng L, Kent J, Loebel A. Efficacy and safety of dasotraline in adults with binge-eating disorder: a randomized, placebo-controlled, fixed-dose clinical trial. CNS Spectr. 2020 May 19:1-10. doi: 10.1017/S1092852920001406. Epub ahead of print. PMID: 32423512.

6: McElroy SL, Hudson JI, Grilo CM, Guerdjikova AI, Deng L, Koblan KS, Goldman R, Navia B, Hopkins S, Loebel A. Efficacy and Safety of Dasotraline in Adults With Binge-Eating Disorder: A Randomized, Placebo-Controlled, Flexible-Dose Clinical Trial. J Clin Psychiatry. 2020 Sep 8;81(5):19m13068. doi: 10.4088/JCP.19m13068. PMID: 32926604.

7: Mosholder AD, Kim J, Davis M, Farchione TR. Re: "Dasotraline in Children with Attention-Deficit/Hyperactivity Disorder: A Six-Week, Placebo-Controlled, Fixed- Dose Trial" by Findling et al. (J Child Adolesc Psychopharmacol 2019;29:80-89). J Child Adolesc Psychopharmacol. 2019 Nov;29(9):725. doi: 10.1089/cap.2019.0061. Epub 2019 May 16. PMID: 31094581.

8: Lew R, Constantinescu CC, Holden D, Carson RE, Carroll V, Galluppi G, Koblan KS, Hopkins SC. The rate of dasotraline brain entry is slow following intravenous administration. Psychopharmacology (Berl). 2020 Nov;237(11):3435-3446. doi: 10.1007/s00213-020-05623-8. Epub 2020 Aug 19. PMID: 32813030; PMCID: PMC7651685.

9: Citrome L. Binge eating disorder revisited: what's new, what's different, what's next. CNS Spectr. 2019 Aug;24(S1):4-13. doi: 10.1017/S1092852919001032. Erratum in: CNS Spectr. 2019 Aug;24(S1):82. PMID: 31196238.

10: Appolinario JC, Nardi AE, McElroy SL. Investigational drugs for the treatment of binge eating disorder (BED): an update. Expert Opin Investig Drugs. 2019 Dec;28(12):1081-1094. doi: 10.1080/13543784.2019.1692813. Epub 2019 Nov 22. PMID: 31714807.